American International Group Inc. Has $1,675,000 Position in Nektar Therapeutics (NKTR)

American International Group Inc. Has $1,675,000 Position in Nektar Therapeutics (NKTR)

American International Group Inc. boosted its position in shares of Nektar Therapeutics (NASDAQ:NKTR) by 0.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,507 shares of the biopharmaceutical company’s stock after buying an additional 3 shares during the period. American International Group Inc. owned 0.07% of Nektar Therapeutics worth $1,675,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Westfield Capital Management Co. LP purchased a new stake in Nektar Therapeutics during the second quarter worth $17,247,000. BlackRock Fund Advisors raised its stake in Nektar Therapeutics by 7.3% in the third quarter. BlackRock Fund Advisors now owns 10,970,974 shares of the biopharmaceutical company’s stock worth $188,481,000 after buying an additional 749,496 shares in the last quarter. Vanguard Group Inc. raised its stake in Nektar Therapeutics by 2.7% in the second quarter. Vanguard Group Inc. now owns 11,650,468 shares of the biopharmaceutical company’s stock worth $165,787,000 after buying an additional 301,245 shares in the last quarter. Marshall Wace LLP purchased a new stake in Nektar Therapeutics during the second quarter worth $3,389,000. Finally, Opaleye Management Inc. raised its stake in Nektar Therapeutics by 440.0% in the second quarter. Opaleye Management Inc. now owns 270,000 shares of the biopharmaceutical company’s stock worth $2,025,000 after buying an additional 220,000 shares in the last quarter. Institutional investors and hedge funds own 85.87% of the company’s stock.

Nektar Therapeutics (NASDAQ:NKTR) traded up 0.98% during trading on Friday, hitting $12.37. 1,475,563 shares of the company were exchanged. Nektar Therapeutics has a 1-year low of $10.52 and a 1-year high of $19.98. The firm’s 50 day moving average price is $12.65 and its 200-day moving average price is $15.07. The stock’s market capitalization is $1.89 billion.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.04. The company had revenue of $36.30 million for the quarter, compared to analyst estimates of $32.42 million. Nektar Therapeutics had a negative return on equity of 8,769.15% and a negative net margin of 98.87%. The firm’s revenue for the quarter was down 39.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.06) EPS. Equities analysts predict that Nektar Therapeutics will post ($1.07) EPS for the current year.

NKTR has been the subject of a number of analyst reports. Piper Jaffray Companies set a $25.00 price objective on shares of Nektar Therapeutics and gave the company a “buy” rating in a research note on Monday, December 12th. Jefferies Group LLC lifted their price target on shares of Nektar Therapeutics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, November 7th. Aegis reiterated a “buy” rating and issued a $21.00 price target on shares of Nektar Therapeutics in a research note on Wednesday, December 28th. Finally, BTIG Research assumed coverage on shares of Nektar Therapeutics in a research note on Friday, January 6th. They issued a “buy” rating and a $22.00 price target for the company. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $20.67.

In other Nektar Therapeutics news, CEO Howard W. Robin sold 87,500 shares of the firm’s stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $12.35, for a total value of $1,080,625.00. Following the completion of the sale, the chief executive officer now directly owns 265,408 shares of the company’s stock, valued at approximately $3,277,788.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Howard W. Robin sold 93,458 shares of the firm’s stock in a transaction on Thursday, November 17th. The stock was sold at an average price of $13.88, for a total value of $1,297,197.04. Following the completion of the sale, the chief executive officer now directly owns 122,908 shares of the company’s stock, valued at $1,705,963.04. The disclosure for this sale can be found here. 6.10% of the stock is owned by company insiders.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Related posts

Leave a Comment